Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
…
continue reading
In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals. The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVi ...
…
continue reading
1
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer
7:26
7:26
나중에 재생
나중에 재생
리스트
좋아요
좋아요
7:26
A large international cohort study has found that women testing positive for the BRCA mutation who chose to breastfeed their babies after treatment for their breast cancer faced no additional risk to their cancer outcomes. OncTimesTalk correspondent Peter Goodwin talked with Eva Blondeaux, MD, Medical Oncologist in the Epidemiology Unit at the IRCC…
…
continue reading
1
Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients
11:33
11:33
나중에 재생
나중에 재생
리스트
좋아요
좋아요
11:33
Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024. In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in…
…
continue reading
1
Findings at ESMO 2024 Highlighting the Benefit of Neoadjuvant Therapies
13:23
13:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:23
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center, Singapore (with a special interest in all asp…
…
continue reading
HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated ca…
…
continue reading
1
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought
4:31
4:31
나중에 재생
나중에 재생
리스트
좋아요
좋아요
4:31
Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the st…
…
continue reading
1
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers
6:28
6:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
6:28
Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting.OncTimesTalk reporter Pete…
…
continue reading
1
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia
7:39
7:39
나중에 재생
나중에 재생
리스트
좋아요
좋아요
7:39
A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of L…
…
continue reading
1
MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival
9:02
9:02
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:02
When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34…
…
continue reading
1
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer
14:15
14:15
나중에 재생
나중에 재생
리스트
좋아요
좋아요
14:15
Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncT…
…
continue reading
1
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes
10:53
10:53
나중에 재생
나중에 재생
리스트
좋아요
좋아요
10:53
The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of N…
…
continue reading
1
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma
11:34
11:34
나중에 재생
나중에 재생
리스트
좋아요
좋아요
11:34
A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut…
…
continue reading
1
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia
9:25
9:25
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:25
Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital,…
…
continue reading
1
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma
6:52
6:52
나중에 재생
나중에 재생
리스트
좋아요
좋아요
6:52
Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the…
…
continue reading
1
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy
8:13
8:13
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:13
Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy. After a…
…
continue reading
1
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
8:50
8:50
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:50
New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progre…
…
continue reading
1
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer
11:34
11:34
나중에 재생
나중에 재생
리스트
좋아요
좋아요
11:34
When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study r…
…
continue reading
1
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic
17:36
17:36
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:36
An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the confe…
…
continue reading
1
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma
10:31
10:31
나중에 재생
나중에 재생
리스트
좋아요
좋아요
10:31
The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group’s early findings of AZD1390, an inhibitor of ataxia telangiectasia …
…
continue reading
1
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC
8:21
8:21
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:21
A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR An…
…
continue reading
1
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes
13:46
13:46
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:46
A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, re…
…
continue reading
1
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic
17:35
17:35
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:35
An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice Pre…
…
continue reading
Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or met…
…
continue reading
1
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers
9:31
9:31
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:31
Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease pr…
…
continue reading
1
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
15:07
15:07
나중에 재생
나중에 재생
리스트
좋아요
좋아요
15:07
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting. After…
…
continue reading
1
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
12:50
12:50
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:50
An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San …
…
continue reading
1
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers
13:00
13:00
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:00
Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in s…
…
continue reading
1
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery
10:27
10:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요
10:27
Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer. At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplina…
…
continue reading
1
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed
8:38
8:38
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:38
The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable effi…
…
continue reading
1
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain
15:40
15:40
나중에 재생
나중에 재생
리스트
좋아요
좋아요
15:40
A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving therapy for ductal carcinoma in situ (DCIS) had become increasingly effective in preventing the emergence of breast cancer over the long term, but that there were still unanswered questions. The populatio…
…
continue reading
1
Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection
9:42
9:42
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:42
Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands. Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department …
…
continue reading
1
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema
34:36
34:36
나중에 재생
나중에 재생
리스트
좋아요
좋아요
34:36
Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool …
…
continue reading
1
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes
8:47
8:47
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:47
New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopaus…
…
continue reading
1
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer
9:00
9:00
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:00
Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference. The researcher…
…
continue reading
1
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer
9:35
9:35
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:35
Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers. These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical …
…
continue reading
1
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab
15:44
15:44
나중에 재생
나중에 재생
리스트
좋아요
좋아요
15:44
About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority. At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Progra…
…
continue reading
1
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia
20:15
20:15
나중에 재생
나중에 재생
리스트
좋아요
좋아요
20:15
An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy. The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are pres…
…
continue reading
1
Important Mantle Cell Lymphoma Findings From the Sympatico Study
13:55
13:55
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:55
How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Ander…
…
continue reading
1
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress
17:44
17:44
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:44
2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to eme…
…
continue reading
1
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
16:00
16:00
나중에 재생
나중에 재생
리스트
좋아요
좋아요
16:00
The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth fac…
…
continue reading
1
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
24:23
24:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
24:23
A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the…
…
continue reading
A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy. At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, rep…
…
continue reading
1
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
18:43
18:43
나중에 재생
나중에 재생
리스트
좋아요
좋아요
18:43
Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy. This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Lo…
…
continue reading
1
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations
8:33
8:33
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:33
The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk corres…
…
continue reading
1
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
15:24
15:24
나중에 재생
나중에 재생
리스트
좋아요
좋아요
15:24
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy…
…
continue reading
1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones
14:51
14:51
나중에 재생
나중에 재생
리스트
좋아요
좋아요
14:51
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn’t be used because of toxicity. At t…
…
continue reading
1
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease
15:43
15:43
나중에 재생
나중에 재생
리스트
좋아요
좋아요
15:43
The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disea…
…
continue reading
1
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma
22:11
22:11
나중에 재생
나중에 재생
리스트
좋아요
좋아요
22:11
With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response r…
…
continue reading
1
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
12:16
12:16
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:16
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.…
…
continue reading
1
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD
12:32
12:32
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:32
In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superio…
…
continue reading
1
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD
14:40
14:40
나중에 재생
나중에 재생
리스트
좋아요
좋아요
14:40
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.
…
continue reading